REP 9AC is the much-anticipated new hepatitis B drug that within weeks suppresses the hepatitis B virus, enabling patients to lose the hepatitis B surface antigen—something no other drug has been able to do. In this latest study, when interferon was added to REP 9AC, patients even developed surface antibodies—essentially permanently getting rid of the infection.
—Christine. M. Kukka, Project Manager, HBV Advocate
"Short Term Immunotherapy Following REP 9AC..." by Al-Mahtab,
and Vaillant. Asian Pacific Association for the Study of Liver
& 15th annual TIDES meeting.